Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind comparison of pegfilgrastim (KRN125) vs filgrastim (KRN8601) for chemotherapy-induced neutropenia in malignant lymphoma
jRCT2080221357Phase 3
- Sponsor
- Kyowa Kirin
- Start
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegfilgrastim in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Kyowa Kirin.
02
Drugs
pegfilgrastim
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on jRCT2080221357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221357.